Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Neoplasms, Castration-Resistant Prostatic Neoplasms, Docetaxel, Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide
Lead Scientists at University of California Health
- Sandy Liu (ucla)
- Edward Uchio, MD,FACS, CPI (uci)
Clinical Professor, Urology, School of Medicine. Authored (or co-authored) 65 research publications
- Lawrence Fong, MD (ucsf)
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center.
- accepting new patients
- Start Date
- Completion Date
- Arcus Biosciences, Inc.
- Phase 1/2 research study
- Study Type
- Expecting 342 study participants
- Last Updated